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ABSTRACT
RNA interference (RNAi) has great potential as a tool
for studying gene function in mammals. However,
the specificity and magnitude of the in vivo res-
ponse to RNAi remains to be fully characterized. A
molecular and phenotypic comparison of a genetic
knockout mouse and the corresponding knockdown
version would help clarify the utility of the RNAi
approach. Here, we used hydrodynamic delivery
of small interfering RNA (siRNA) to knockdown
peroxisome proliferator activated receptor alpha
(Ppara), a gene that is central to the regulation of
fatty acid metabolism. We found that Ppara knock-
down in the liver results in a transcript profile and
metabolic phenotype that is comparable to those of
Ppara
 /  mice. Combining the profiles from mice
treated with the PPARa agonist fenofibrate, we
confirmed the specificity of the RNAi response and
identified candidate genes proximal to PPARa regu-
lation. Ppara knockdown animals developed hypo-
glycemia and hypertriglyceridemia, phenotypes
observed in Ppara
 /  mice. In contrast to Ppara
 / 
mice, fasting was not required to uncover these
phenotypes. Together, these data validate the utility
of the RNAi approach and suggest that siRNA can
be used as a complement to classical knockout
technology in gene function studies.
INTRODUCTION
The use of genetic knockout mice has greatly facilitated the
study of gene function in a wide range of biological processes
and has aided in the discovery of new therapeutics. Indeed, a
retrospective investigation of knockouts of top-selling drug
targets revealed a correlation between phenotypes, mecha-
nism of action and therapeutic effectiveness (1). However,
there are drawbacks to the use of knockout technology.
These include the time required to generate the founder
knockout animal and to breed a population of sufﬁcient size
for the acquisition of statistically signiﬁcant data, the difﬁ-
culties in generating knockout animals for embryonic lethal
genes and the fact that knockout technology is practically
limited to a few strains of mice and not readily applicable
for use in other species.
The discovery that small interfering RNA (siRNA) could
be used in mammalian cells to elicit RNA interference
(RNAi) has opened another avenue for studying gene func-
tion in mammals (2). The use of siRNA could circumvent
some limitations of knockout technology, allowing rapid
generation of relatively large numbers of knockdown mice
of practically any strain of interest. Indeed, there have been
several recent reports of the use of RNAi in mice [reviewed
in (3)]. However, the paucity of data detailing the molecular
and phenotypic effects of delivering siRNA and of the subse-
quent knockdown of target gene expression in these studies
has made it difﬁcult to deﬁnitively discern the effectiveness
and speciﬁcity of the RNAi approach. Here, we performed
a molecular and phenotypic comparison of mice treated
with siRNA targeting peroxisomal proliferator activated
receptor alpha (Ppara) and Ppara knockout mice.
Ppara is a member of the nuclear hormone receptor super-
family and is involved in regulating fatty acid metabolism. In
the liver, Ppara is expressed exclusively in hepatocytes (4).
During an overnight or prolonged fast, fatty acids released
from adipose tissue are transported to the liver, robustly
inducing PPARa activity (5). Upon binding fatty acid ligand,
PPARa stimulates transcription of genes containing PPARa
response elements in their enhancers, most notably genes
involved in lipid metabolism and energy homeostasis (6).
Drugs belonging to the ﬁbrate class act as synthetic PPARa
ligands and can be used to treat patients with hypertriglyc-
eridemia. Consistent with the proposed role for PPARa,
these drugs improve plasma lipid proﬁles by promoting
fatty acid b-oxidation and reducing hepatic triglyceride
production.
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 /  mice have provided valuable insight
into the role of PPARa in regulating metabolism. Interest-
ingly, young adult Ppara
 /  mice have slightly elevated
levels of cholesterol but do not display an obvious phenotype
under normal dietary conditions (7,8). However, under fast-
ing conditions or when fed a high fat diet, these mice suffer
from hypoglycemia and dyslipidemia, and accumulate mas-
sive amounts of lipid in their livers (5,7,9). These phenotypes
can be partially explained by an inability of the Ppara
 / 
mice to meet energy demands and a rate of fatty acid uptake
by the liver that exceeds the capacity of the liver to secrete
triacylglycerols. In contrast to young adult Ppara
 /  mice,
aged Ppara
 /  mice are obese and have increased serum
triglycerides in the absence of fasting (10). These phenotypes
were found to be sexually dimorphic, being more pronounced
in females than in males.
In this study, we used hydrodynamic tail vein injection
to deliver siRNA targeting Ppara and compared resulting
genome-wide transcriptional proﬁles and phenotypes to
those of Ppara
 /  mice. We found that knockdown of Ppara
using RNAi results in a transcript proﬁle in the liver that is
highly comparable, both in magnitude and direction, to that
observed in Ppara
 /  mice. Phenotypic analyses revealed
that siRNA-treated mice displayed hypoglycemia and hyper-
triglyceridemia, phenotypes observed in similarly aged
Ppara
 /  mice. Together, these results indicate that hydro-
dynamic delivery of siRNA can be effectively used to study
gene function in the liver of mice.
MATERIALS AND METHODS
siRNAs
The siRNAs used in this study were obtained from
Dharmacon and consisted of 21 nt sense and antisense
oligonucleotides each containing ﬂuoro substitutions at the
20 position of pyrimidine nulceotides, a 50-PO4 and a two
deoxynucleotide overhang at the 30 end. The 20ACE protec-
ted oligonucleotides were puriﬁed by HPLC and then depro-
tected according to the manufacturer’s instructions. Control
siRNA targeting the secreted alkaline phosphatase reporter
gene (SEAP, GenBank accession no. U89937): sense 50-
pAGGGcAAcuuccAGAccAudTdT-30, antisense 50-pAuG-
GucuGGAAGuuGcccudTdT-30; Ppara (GenBank accession
no. NM_011144) siRNA#1: sense 50-pGAucGGAGcuGc-
AAGAuucdAdT-30, antisense 50-pGGAucuuGcAGcuccGA-
ucdAdT-30; Ppara siRNA#2: sense 50-pucAcGGAGcu-
cAcAGAAuudCdT-30, antisense 50-pAAuucuGuGAGcuccG-
uGAdCdT-30; Ppara siRNA#3: sense 50-pGAAGuucAAu-
GccuuAGAAdAdT-30, antisense 50-puucuAAGGcAuuGGA-
cuucdAdT-30. Nucleotides containing 20-ﬂuoro substitutions
are lower-case; d, deoxynucleotides; p, 50 PO4. Sense and
antisense oligonucleotides for each target sequence were
annealed by mixing equimolar amounts of each and heating
to 94 C for 5 min, cooling to 90 C for 3 min, then decreasing
the temperature in 0.3 C steps 250 times, holding at each step
for 3 s.
Primary hepatocyte isolation and transfection
Primary hepatocytes were harvested from adult mice (strain
C57BL/6) using the two-step collagenase perfusion procedure
as described previously (11). Hepatocyte viability was
85–90% as determined by Trypan blue exclusion. Hepato-
cytes were plated at a density of 1.5 · 10
5 cells per well in
collagen coated 12-well plates. Cells in triplicate wells
were transfected with siRNA at a ﬁnal concentration of
100 nM using TransIT -siQuest (Mirus Bio Corporation)
according to the manufacturer’s protocol, 24 h post plating.
Hepatocytes were harvested 24 h after transfection and total
RNA was isolated with Tri Reagent (MRC, Inc.).
Mice and injection procedures
All animal studies were conducted at Mirus Bio Corporation
with approval from Mirus’ Institutional Animal Care and Use
Committee. Six- to eight-week-old mice (strain C57BL/6,
19–21 g) were obtained from Harlan Sprague Dawley Inc.
and housed at least 10 days on a 12 h light/dark cycle before
injection. Mice had free access to food and water throughout
the course of the experiments (Harlan Teklad Rodent Diet).
For siRNA delivery, mice were injected in the tail vein
using the hydrodynamic technique without anaesthesia as
described previously (12). Brieﬂy, siRNA (40 mg) was diluted
in a volume of Ringer’s solution (147 mM NaCl, 4 mM KCl
and 1.13 mM CaCl2) equal to 10% of the animal’s body
weight. The entire volume was injected into the tail vein in
5–7 s using a 3 ml syringe ﬁtted with a 27 gauge needle.
Liver harvest and RNA isolation
Mice had free access to food throughout the duration of the
experiments and were sacriﬁced within 1 h of each other.
Total RNA was isolated from mouse liver using the RNeasy
Midi Kit (Qiagen) according to the manufacturer’s protocol
with minor modiﬁcation. Brieﬂy, mouse liver was harvested
and immediately placed in 30 ml of RLT buffer and homoge-
nized for 45 s using a PRO200 homogenizer (PRO Scientiﬁc).
Homogenates were spun at 4000 r.p.m. for 20 min in a RT7
Plus centrifuge (Sorvall). Supernatant (2 ml) was transferred
to a new tube and 1 vol of 50% ethanol was added before
loading the RNeasy column. The manufacturer’s protocol
was followed for the rest of the procedure.
Quantitative PCR Assays
Total RNA (500 ng) was reverse transcribed using Super-
Script III (Invitrogen) and oligo-dT primers according to
the manufacturer’s protocol. Quantiﬁcation of gene-speciﬁc
mRNA levels was performed by RT-qPCR using an iCycler
iQ system (Bio-Rad). Relative levels of Ppara and GAPDH
mRNA were measured in biplex reactions performed in
triplicate using TaqMan  Universal PCR Master Mix and
the TaqMan  Gene Expression Assay for Ppara (Applied
Biosystems) as per the manufacturer’s protocol. The GAPDH
primers and probe (IDT) were as follows: GAPDH-forward,
50-AAATGGTGAAGGTCGGTGTG-30;G A P D H - r e v e r s e ,
50-CATGTAGTTGAGGTCAATGAAGG-30;a n dG A P D H -
probe, 50-Hex/CGTGCCGCCTGGAGAAACCTGCC/BHQ-30.
Microarray procedures
Expression proﬁling was carried out using custom arrays
consisting of  23 000 60mer oligonucleotides (plus control
sequences) representing mouse genes as described previously
(13). All hybridizations were performed in duplicate, with
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knockdown mice, each experiment consisted of three groups
injected either with Ppara siRNA, control siRNA or injection
buffer alone (Ringer’s). RNAs from individual siRNA-treated
animals and buffer-treated animals were hybridized against a
pool of RNA from time-matched buffer-treated animals.
Ppara
 /  mice originated from the colony established at
the National Cancer Institute (8). For fenoﬁbrate treatment
(200 mg/kg/day) wild-type (C57BL/6) and Ppara
 /  mice
(6 animals per group) were treated for 1 and 7 days. RNA
from individual animals were paired according to their
genetic background and hybridized against a pool of RNA
(6 animals) from time-matched wild-type or Ppara
 / 
mice, respectively. The transcriptional response for Ppara
 / 
mice was determined by hybridization of RNA against a
wild-type pool.
Statistical tests
Signiﬁcance between groups was determined using a two-
tailed t-test of either unequal [e.g. Experiments A and B,
treatments (n > 15) versus control siRNA (n ¼ 4)] or equal
variance [e.g. Experiment C (n ¼ 4)]. The signiﬁcance of
Pearson product-moment correlation coefﬁcients (r) was




N   2
1   r2
r
df ¼ N   2‚
where N ¼ number of pairs.
RESULTS
Delivery of Ppara siRNA to mice by hydrodynamic
injection results in knockdown of Ppara expression
in liver
We ﬁrst screened ﬁve siRNAs against Ppara for activity
using mouse primary hepatocytes. In anticipation of in vivo
studies, the siRNAs were synthesized with 20F substitutions
on pyrimidines and 20-H substitutions in the 2 nt at each 30
end to increase nuclease resistance. We found that three of
the ﬁve siRNAs (Ppara siRNA#1, #2 and #3) were highly
active in this in vitro system (Figure 1A).
Our initial studies in mice were composed of two indepen-
dent experiments, A and B. In both experiments, Ppara
siRNA#1 (40 mg) was delivered to 6- to 8-week-old C57Bl/
6 female mice using hydrodynamic tail vein injection. Con-
trol groups included mice injected with a non-targeting
siRNA (control siRNA) or Ringer’s buffer alone. Livers
were harvested 24 h after injection. A pairwise comparison
of the Ppara siRNA-treated groups to the groups treated
with control siRNA revealed a signiﬁcant (P < 0.01) average
reduction in Ppara mRNA as determined by quantitative
PCR (RT-qPCR) (Figure 1B). The Ppara RT-qPCR data
across all individuals in our studies correlated signiﬁcantly
(r ¼ 0.81, P < 0.001) with Ppara expression in individuals
for which data were obtained from high-density microarrays
(Figure 1C). The data indicated that the amount of Ppara
knockdown was variable between mice, ranging from  80%
knockdown to little or no apparent knockdown. This is likely
due to variable siRNA delivery efﬁciency.
Genome-wide transcript profiles of Ppara
siRNA-treated mice and Ppara
 /  mice are concordant
We utilized high-density microarrays to compare the genome-
wide transcriptional response in liver of mice injected with
Ppara siRNA#1 to that of the well-characterized Ppara
 / 
mouse (8). Knockdown mice from Experiment A were used
for these initial analyses. Using the ROAST  correlation
tool in the Resolver  v5.0 gene expression data analysis
system, we identiﬁed 622 genes that correlated (r > 0.7,
P < 1 · 10
 8) with Ppara expression levels. The transcrip-
tional response for these 622 genes when projected onto the
microarray responses of Ppara
 /  mice revealed high con-
cordance, both in direction and magnitude, with that observed
with Ppara siRNA#1-treated animals (Figure 2). Transcrip-
tional concordance was also maintained with larger gene
sets (3295 genes) representing lower Ppara correlation
thresholds (r > 0.5, P < 1 · 10
 5, data not shown). Accord-
ingly, the majority of mice treated with Ppara siRNA#1
grouped with Ppara
 /  mice. However, three mice, Ppara
siRNA#1 animals 15, 17 and 19, grouped in the clade con-
taining the mice injected with control siRNA or Ringer’s
buffer alone (Controls, Figure 2). These mice showed little
to no Ppara knockdown by RT-qPCR and may represent
animals with suboptimal siRNA delivery (Figure 1B). Upon
visual inspection, the transcript proﬁles of these three animals
does reveal some resemblance to those within the clade
containing the majority of the Ppara siRNA#1-treated and
the Ppara
 /  mice. The magnitude of the response in these
three mice was very low and is likely to be the reason why
these animals group in the clade dominated by the control
animals. There were other Ppara siRNA#1-treated mice
displaying only apparently slight Ppara knockdown that did
group in the clade containing Ppara
 /  mice. It is possible
that it is the change in Ppara levels that is important for per-
turbing expression of genes modulated by Ppara rather than
the absolute levels of Ppara. If the pre-injection levels of
Ppara expression in these animals were higher than average,
then this change would be reﬂected in the overall transcrip-
tional response to Ppara knockdown as observed here, and
not necessarily in the absolute level of Ppara expression.
Identification of proximal transcriptional responses
to Ppara perturbation
In the following analyses, the transcript proﬁles of Ppara
knockdown and Ppara
 /  mice were compared to those of
wild-type mice treated with the PPARa agonist fenoﬁbrate in
order to identify candidate genes that are proximal to PPARa
regulation as well as to further conﬁrm the speciﬁcity of the
siRNA response (14). Although PPARa agonism is not the pre-
cise opposite of Ppara knockdown, we expected that genes
proximal to PPARa regulation would be oppositely regulated
in the two scenarios. Proﬁles of knockdown mice from Experi-
ments A and B were included in this analysis as well as mice
from a third experiment, Experiment C, in which Ppara
siRNA#1, #2 or #3 were injected and livers harvested at 24,
48 or 96 h. The use of three different siRNAs targeting
Ppara in Experiment C would help to ensure the proﬁles
4488 Nucleic Acids Research, 2006, Vol. 34, No. 16obtained were speciﬁc for Ppara knockdown and not due to off-
target effects of any individual siRNA. A timecourse would
allow us to determine the duration of the siRNA effect.
k-means clustering was used to separate the 622 genes
modulated by Ppara siRNA treatment shown in Figure 2
into eight sets (Figure 3A, x-axis). Two of the sets, sets
1 and 7, were composed of 71 genes that were oppositely
regulated between fenoﬁbrate-treated mice, and Ppara
siRNA-treated and Ppara
 /  mice. When compared to the
Gene Ontology (GO) gene sets for Biological Process anno-
tation, these gene sets had signiﬁcant correlation to metabolic
pathways pertaining to oxidative phosphorylation (P ¼ 1.16 ·
10
 6) and fatty acid b oxidation (P ¼ 5.50 · 10
 3), respec-
tively (Table 1). These two pathways have in common the
fatty acid metabolic intermediate acetyl-CoA and are
known to be directly regulated by PPARa (5). Thus, gene
Figure 1. Ppara knockdown with modified siRNAs in vitro and in vivo.( A) Identification of active Ppara siRNAs using transfection of primary mouse
hepatocytes. Ppara RT-qPCR measurements are normalized to either GAPDH mRNA or input RNA and are expressed relative to the control siRNA group mean.
Bars represent the mean (±SD) for n ¼ 3. (B) In vivo Ppara knockdown. Ppara RT-qPCR measurements are normalized to GAPDH mRNA and are expressed
relative to the buffer group mean. Shown are responses to Ppara siRNA#1 treatment at 24 h for individual animals in Experiments A and B. S, Ppara siRNA#1;
CS, control siRNA; B, injection buffer only. Line indicates 2 SDs below the buffer group mean. Inset, group means (±SEM); y-axis is %/100; *, P < 0.01; **,
P ¼ 0.01. (C) Regression analysis between microarray and RT-qPCR measurements for Ppara mRNA in vivo. For microarray measurements, individual animal
data is expressed relative to the pool of buffer only treated animals. For RT-qPCR measurements, individual animal data are expressed relative to the appropriate
buffer group mean. Shown are the Ppara mRNA levels for mice in Experiments A, B and C. Animal 20 (Experiment A) and animals 11–15 (Experiment B)
were not profiled and are not represented on the chart. Closed circles, Ppara siRNA-treated animals; open circles, buffer and control siRNA-treated animals.
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Ppara regulation. In addition, the fact that the genes in sets 1
and 7 show decreased expression in Ppara knockdown and
Ppara
 /  mice and increased expression upon fenoﬁbrate
treatment is evidence for the on-target effects of the Ppara
siRNAs used. Two of the remaining gene sets, sets 5 and 8,
were also identiﬁed to have signiﬁcant (P < 0.01) overlap with
other GO gene sets (Table 1). Gene set 8 correlated with
components of the ubiquitin-proteosome system and gene
set 5 with those involved in mRNA processing. It has been
shown that PPARa activity is controlled by regulating stabil-
ity at the protein level and that Ppara mRNA levels are
increased during fasting (5,15). Given the important role of
PPARa in regulating fatty acid and glucose metabolism,
modulation of these systems may be indicative of compen-
satory mechanisms utilized to maintain metabolic homeosta-
sis when expression or activity of Ppara is perturbed.
Together, these observations are consistent with the known
proximal on-target effects of Ppara deﬁciency (gene sets
1 and 7) and putative distal responses to Ppara perturbation
(gene sets 2–6 and 8).
Unsupervised agglomerative clustering of all mice using
gene sets 1 and 7 resulted in two major experimental clades
(Figure 3A, y-axis). Clade 1 consists of Ppara siRNA#1,
#2 and #3-treated mice at 24, 48 and 96 h post administration
(with two exceptions) together with the Ppara
 /  mice. Thus,
the signatures of mice treated with three different Ppara
siRNAs are similar to that of Ppara
 /  mice, with the effect
of the siRNAs persisting to at least 96 h post administration.
The fact that a similar signature was obtained using three dif-
ferent Ppara siRNAs is evidence that any potential off-target
effects of individual siRNAs did not signiﬁcantly affect the
outcome. Clade 2 consists primarily of mice receiving control
treatments (highlighted in red). A few Ppara siRNA-treated
animals are also found in Clade 2. These mice had only a
weak signature for genes in sets 1 and 7 used for the cluster
analysis, and their presence in Clade 2 likely due to subopti-
mal siRNA delivery. Conversely, 2 of 56 control mice had
signatures of sufﬁcient similarity to Ppara knockdown and
knockout mice that they were grouped into Clade 1. It is
known that Ppara expression levels are modulated by dietary
intake (5,9). Even though all mice had free access to food for
Figure 2. Transcriptional concordance between Ppara knockdown and Ppara
-/- animals. Genes correlating to Ppara in Experiment A mice were identified by the
ROAST  correlation tool in Resolver  v5.0 gene expression data analysis system. Represented is unsupervised agglomerative clustering of 44 experiments
(heuristic criteria: Wards minimum variance, similarity measure: Manhattan distance) and 622 genes (heuristic criteria: average link, similarity measure:
Euclidean distance). Mice highlighted in blue and red represent treatment and control administrations, respectively.
4490 Nucleic Acids Research, 2006, Vol. 34, No. 16the duration of the experiments, minor variations in Ppara
expression due to different feeding behaviours among
individual mice were not unexpected. These minor differ-
ences appear to be reﬂected at least to some extent in the
transcript proﬁles of two of the control mice.
We also note that for six of the animals treated with Ppara
siRNAs in Experiment C a markedly different transcription
signature was observed (data not shown). We were unable
to reproduce this response in independent experiments, and
as the signature was sufﬁciently high to obscure our analyses
Figure 3. On-target responses to Ppara perturbation. Mice highlighted in blue and red represent treatment and control administrations, respectively. (A) Gene
sets 1–8 were identified by k-means clustering (similarity measure: Euclidean distance, sorted by deviation) of the 622 genes that have significant transcriptional
correlation (r > 0.7, P < 1 · 10
 8)t oPpara across Experiments A and B. Genes in sets 1 and 7 (representing proximal Ppara on-target responses, see text) were
used for agglomerative clustering (heuristic criteria: Wards minimum variance, similarity measure: maximum distance) of the 125 transcriptional responses
illustrated and the results are projected onto all the gene sets identified through k-means clustering. Evident are two experimental clades comprised
predominantly of mice treated with Ppara siRNA #1, #2 and #3 and harvested at 24, 48 and 96 h after injection (Clade 1) and mice treated with buffer only or
control siRNA (Clade 2). (B) Unsupervised agglomerative clustering of 9 genes (heuristic criteria: Wards minimum variance, similarity measure: Manhattan
distance) reported to have functional PPREs in their promoters and under the control of Ppara, and the 125 transcriptional responses (heuristic criteria: average
link, similarity measure: Euclidean distance). Evident are two experimental clades comprised predominantly of mice treated with Ppara siRNA (Clade 1) and
mice treated with buffer only or control siRNA (Clade 2).
Nucleic Acids Research, 2006, Vol. 34, No. 16 4491these mice were excluded. We did not detect evidence of an
interferon-like transcriptional response in siRNA-treated ani-
mals in any of our experiments, consistent with previous
reports using hydrodynamic delivery of naked siRNA (16).
Treatment with Ppara siRNA alters expression
of known PPARa targets
As a ﬁnal test of the speciﬁcity of the transcriptional response
to Ppara knockdown, we identiﬁed nine genes present on our
microarray and reported in the literature to have functional
(i.e. demonstrated by transfection and/or DNA binding
assays) peroxisome proliferator response elements (PPREs)
in their promoters (17–25). Unsupervised agglomerative clus-
tering of all 125 transcription signatures revealed that genes
with functional PPREs were predominantly down-regulated
in Ppara siRNA-treated animals (Figure 3B, Clade 1). In
addition, all nine genes investigated were up-regulated with
the PPARa agonist fenoﬁbrate, lending support to this ration-
ale for identifying proximal Ppara regulated candidate genes
as described in the previous section.
Mice treated with Ppara siRNA display a similar
but distinct phenotype to Ppara
 /  mice
The phenotype of Ppara
 /  mice is readily apparent after
fasting and includes decreased blood glucose levels and
increased triglycerides (5,9,26). To determine the phenotypic
effect of Ppara knockdown, we collected blood from mice
prior to delivery of Ppara siRNA#1, and then at 24 h (Experi-
ments A and C), 48 h (Experiment C) and 96 h (Experiment C)
after siRNA delivery and performed assays for the appropriate
Figure 4. Effects of Ppara siRNA treatment on plasma concentrations of glucose and triglyceride. (A) Glucose and triglyceride group means of mice in
Experiment A (±SEM). (B) Experiment A individual animal responses for glucose (triangles) and triglyceride (circles) relative to microarray measurements for
Ppara mRNA (Materials and Methods). Closed symbols, siRNA#1-treated animals; open symbols, control siRNA and buffer-treated animals. (C and D)
Experiment C glucose and triglyceride group means (±SEM), respectively. *P < 0.01; **P < 0.05. Pre-injection data were subtracted from experimental values to
compensate for base-line drift. Female mice were used in Experiment A and male mice in Experiment C.
Table 1. Gene Ontology Process annotations associated with gene sets 1 to 8
Set # Genes GO Process annotation P-value threshold (P < 0.01) Gene symbol
1 53 energy pathways 2.12E-07 1110020P15Rik, Acads,
oxidative phosphorylation 1.16E-06 Aco2, Atp5d, Atp5g2, Atp5o,
ATP synthesis coupled electron transport (sensu Eukaryota) 1.00E-04 Coasy, Cox7b, Cpt1a, Cpt2,
ATP synthesis coupled electron transport 1.00E-04 Etfb, Ndufs7, Sdhc, Slc25a10,
electron transport 1.98E-04 Uqcr, Uqcrb
energy derivation by oxidation of organic compounds 2.96E-03
group transfer coenzyme metabolism 4.16E-03
23 1 N S
3 105 NS
4 132 NS
5 104 mRNA processing 8.12E-03 Fip1/1, Fnbp3, Hnrpa3,
Rbms2, Rngtt, Sfrs1, Son,
Ssb
64 9 N S
7 18 fatty acid metabolism 2.01E-05 Acadvl, Decr2, Hsd17b4,
very-long-chain fatty acid metabolism 2.46E-04 Peci, Slc25a20
peroxisome organization and biogenesis 6.93E-04
fatty acid beta-oxidation 5.50E-03
8 130 ubiquitin cycle 2.57E-04 Fbxl10, Herc2, Hip2, Pja2,
ubiquitin-dependent protein catabolism 7.54E-04 Psmd2, Rnf11, Senp2, Ube1x,
modification-dependent protein catabolism 8.48E-04 Ube2n, Ube2v2, Usp4, Usp47,
Usp48
NS ¼ not significant.
4492 Nucleic Acids Research, 2006, Vol. 34, No. 16physiological markers. In these analyses, mice had free
access to food and were not purposely fasted before, during
or after siRNA delivery.
As expected, we observed an increase in ALT and AST
levels in the serum at 24 h due to the effects of the hydrodyn-
amic injection method in the liver. However, these returned
to near normal levels by 96 h, and were not signiﬁcantly
different between treated and control groups. In contrast, a
group comparison of the Ppara siRNA#1-treated animals to
those treated with control siRNA in Experiment A revealed
a signiﬁcant decrease in plasma glucose (P < 0.05) and
increase in triglyceride (P < 0.01) concentrations 24 h after
siRNA delivery (Figure 4A). Ppara knockdown as deter-
mined by microarrays relative to all Experiment A animals
correlated signiﬁcantly with modulations in glucose
(r ¼ 0.59, P < 0.01) and triglyceride (r ¼  0.60, P <
0.001) concentrations (Figure 4B). The fact that these pheno-
types were observed in the absence of fasting is contradictory
to the situation in similarly aged Ppara
 /  mice, where fast-
ing is required. These data indicate that knockdown of Ppara
expression using siRNA yields a phenotype consistent with
the known function of Ppara, but one that does not fully
recapitulate that of the knockout.
In Experiment C, the treatment related trend for both
plasma glucose and triglyceride concentrations was consistent
with ﬁndings in Experiment A. However, the decrease
in blood glucose observed in mice treated with Ppara
siRNA#1 compared to control mice was not above a statisti-
cally signiﬁcant threshold in Experiment C (Figure 4C),
despite the fact that Ppara knockdown by siRNA#1 in
Experiment C at 24 h was on average equivalent to that
observed in Experiment A. The increase in blood triglyceride
concentration was statistically signiﬁcant at 48 h (P ¼ 0.02),
but increased below a statistically signiﬁcant threshold at 24 h
(P ¼ 0.20) and 96 h (P ¼ 0.41) (Figure 4D). One possible
explanation for the less pronounced phenotype observed in
Experiment C versus Experiment A mice may lie in the
fact that the Experiment C mice were male, whereas Experi-
ment A mice were female. Sexually dimorphic responses
have been reported previously in Ppara
 /  mice (10,27).
DISCUSSION
The main objective of this study was to determine if delivery
of naked siRNA using hydrodynamic tail vein injection
would result in functional inhibition of target gene express-
ion in mouse liver. We chose to target Ppara, a well-
characterized gene that is critically important in fatty acid
metabolism, for which a genetic knockout exists, and
whose protein product is the target of therapeutically relevant
drugs. We obtained several lines of evidence indicating that
delivery of Ppara siRNA induced target-speciﬁc inhibition.
First, quantiﬁcation of Ppara mRNA levels by RT-qPCR or
microarrays indicated a signiﬁcant reduction in mice receiv-
ing Ppara siRNA compared to those receiving a control.
Second, we observed high-transcriptional concordance in
both magnitude and direction between Ppara siRNA-treated
mice and in Ppara
 /  mice using genome-wide transcrip-
tional proﬁling. The transcriptional changes were maintained
for at least 96 h and were evident with three different siRNAs.
Third, sets of genes were identiﬁed that were oppositely regu-
lated in siRNA-treated mice compared to mice treated with
the PPARa agonist fenoﬁbrate. These gene sets were highly
correlated with GO gene sets pertaining to oxidative phos-
phorylation and fatty acid b oxidation, processes shown pre-
viously to be directly regulated by PPARa (5). Fourth, genes
known to contain functional PPARa-binding sites in their
enhancers were expressed at lower levels in mice receiving
Ppara siRNA than in control mice. Finally, mice treated
with Ppara siRNA displayed phenotypes similar to those
observed in Ppara
 /  mice, namely hypoglycemia and hyper-
triglyceridemia. Thus, both molecular and phenotypic data
indicate that functional delivery of naked siRNA to the
liver was achieved.
Although the phenotypes of animals treated with Ppara
siRNA were similar to those reported for Ppara
 /  mice,
we also noted important differences. The most signiﬁcant
difference was the appearance of hypoglycemia and hyper-
triglyceridemia in Ppara siRNA-treated animals in the
absence of fasting. This suggests that Ppara functions to
maintain lipid and glucose homeostasis regardless of the fed
state of the animal. This was an unexpected ﬁnding given
the requirement for fasting to uncover the phenotypes in
Ppara
 /  mice. It is possible that in Ppara
 /  mice, which
are devoid of Ppara function throughout development, com-
pensatory mechanisms are induced during growth and devel-
opment that are sufﬁcient to maintain homeostasis in the fed
state, but insufﬁcient in the fasted state. Fasting places a
greater reliance on fatty acid oxidation in the liver, which
is required to generate ketone bodies needed to supply the
energy needs of tissues such as muscle and brain (28). In ani-
mals treated with Ppara siRNA, we speculate that Ppara
expression is inhibited before the putative compensatory
mechanisms can be fully induced. Alternatively, it is possible
that the lack of complete knockdown impacted the pheno-
types we observed in the knockdown mice versus those of
the Ppara
 /  mice. We cannot differentiate these possibilities
based on the data presented in this report.
How an animal responds to decreased Ppara function may
also depend on its gender. In our study, we observed more
dramatic phenotypes in female versus male mice treated
with siRNA. Gender-related differences in the phenotypes
of Ppara
 /  mice have also been noted. Djouadi et al. (27)
found that inhibition of fatty acid oxidation in Ppara
 / 
mice by administration of an irreversible inhibitor of carnitine
palmitoyltransferase I resulted in more severe phenotypes in
males than in females. These phenotypes could be rescued
by pre-treatment with estradiol. In aged Ppara
 /  mice,
Costet et al. (10) reported sexually dimorphic phenotypes
including obesity and increased serum triglyceride levels in
females, and steatosis and increased hepatic triglyceride
levels in males. Together, these studies and the present one
indicate that the gender of the animal affects how it responds
to perturbations in Ppara expression.
We have shown here that a single hydrodynamic tail vein
injection of a relatively small dose of naked siRNA leads to
inhibition of Ppara expression in mouse liver to biological
effect. These results suggest that this method can be used as
a means to uncover gene function in vivo. However, there
are caveats to the use of siRNA including the potential of
off-target effects, incomplete knockdown and non-targeting
Nucleic Acids Research, 2006, Vol. 34, No. 16 4493of splice variants by the selected siRNA sequence. The use of
multiple siRNAs aids in determining if the observed results
are due to inactivation of the target gene itself and not due
to other effects. Incomplete knockdown of target gene func-
tion as well as the transient nature of knockdown using
siRNA may also impact the severity and speciﬁcs of the
phenotype observed. The use of traditional gene knockout
technology would be preferable to gene knockdown technol-
ogy in this sense. However, the cost and time required to gen-
erate knockout mice is substantial. In light of this, one
potential application of the siRNA approach would be as a
screening method to gain insight on the phenotypes of large
numbers of genes quickly. The function of the genes identi-
ﬁed in the RNAi screen could then be veriﬁed or analyzed
in more detail by creating knockout strains. The data pre-
sented in this report indicate that this could be a viable strat-
egy for gaining an understanding of gene function in liver.
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